TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with PNH~* Have received at least one red blood cell transfusion within last 12 weeks~* Anemia with adequate reticulocytosis~* Must be on a stable regimen of eculizumab~* Platelet count ≥ 40,000/microliter without the need for platelet transfusions~* Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae or willingness to receive vaccinations based on local guidelines~* Willingness to receive antibiotic prophylaxis~* Female participants must use highly effective birth control to prevent pregnancy during the clinical trial and for 30 days after their last dose of study drug~* Male participants must use a highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 90 days after the last dose of study drug~Key Exclusion Criteria:~* Current evidence of bone marrow failure or aplastic anemia requiring treatment~* History of a major organ transplant or hematopoietic stem cell/marrow transplant~* Received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater~* Documented C5 complement protein mutations~* Known or suspected complement deficiency~* Contraindication to any of the required vaccinations~* Active bacterial infection or clinically significant active viral infection, a body temperature \>38°C, or other evidence of infection~* History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection~* History of hypersensitivity reactions to commonly used antibacterial agents~Note: Additional inclusion/exclusion criteria may apply, per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: 100 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100 mg danicopan TID in combination with eculizumab.
- Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
- Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
- Group 4: Optimal Dose of Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Reported Effectiveness and Safety of Etoricoxib in Osteoarthritis (OA)(0663-113)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must Be Over 20 Years Of Age, Regardless Of Sex~* Must Have A Diagnosis Of OA That Requiring Treatment~* Patients Must Have Taken an NSAID, Cox-2 Or Opioids On The Majority Of Days During The Last 4 Weeks Before Enrollment Who Are Intolerant (Due To Gastrointestinal Adverse Events) Or Inadequately Respond To Current Therapy (Vas \>= 40 mm On A Pain Scale From 0-100 mm)~* Excluding Osteoarthritis, The Patient Is Judged To Be In Otherwise General Good Health Based On Medical History, Physical Examination, And Routine Laboratory Tests~* Must Agree To Participate Voluntarily In The Study~* Must Have The Capacity To Understand And Answer The Questionnaires Used In The Study~* Must Agree To Return For A Follow-Up Visit With The Treating Physician Four Weeks After The Initiation Of Treatment With Etoricoxib~* Patient Is Willing To Sign Informed Consent Form~Exclusion Criteria:~* Under 20 Years Of Age~* Severe Hepatic Insufficiency (Child-Pugh Score \> 9)~* Advanced Renal Insufficiency (Creatinine Clearance \< 30 Ml/Min)~* Any Contraindication Or Warning Or Precaution As Mentioned In The Approved Study Drug Package Insert~* Gi Ulcer With Active Bleeding Present At Study Enrollment~* Patient Has A Recent History Of Stroke, Myocardial Infarction Or Transient Ischemic Attack (Within The Previous 2 Years)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Etoricoxib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Proglucamune in the Treatment of Protective Qi Insufficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or females aged 18 to 65 years (inclusive) without regard to race or ethnic background~2. Provide a signed Informed Consent prior to entry in the study.~3. Willing to follow all study instructions and consume the assigned investigational product for 8 weeks.~4. Not currently taking a beta-glucan containing supplement or any other supplement that might interfere with the study design.~5. Ability to swallow tablets and pills.~6. Diagnosed as having Qi deficiency based on the following criteria:~   * exhibit a history of susceptibility to cold\* (\* as defined in Traditional Chinese Medicine, TCM)~  * exhibit a shortness of breath~  * exhibit a lack of energy or excessive fatigue~  * susceptible to spontaneous perspiration~  * exhibit a corpulent tongue with or without white fur~  * unwillingness to speak~  * weak or powerless pulse~  * pale complexion~Exclusion Criteria:~1. Persons diagnosed by TCM as having medical conditions other than low Qi.~2. Significant acute or chronic illness or other medical conditions that will prevent or interfere with giving an informed consent, or with participation in the study.~3. Persons with insulin-dependent and orally controlled diabetes will also be excluded from the study.~4. Scheduling difficulties or lack of transportation that will prevent or interfere with their ability to attend all of the necessary study visits.~5. Persons medically diagnosed with depression or anxiety disorders.~6. Persons with a history of alcohol abuse or other substance abuse within the previous 2 years.~7. Females who are attempting to become pregnant, pregnant, lactating or who have given birth within 1 year.~8. Persons who have had a medical surgery in the past 4 weeks.~9. Persons currently enrolled in a clinical trial, or who have completed a clinical trial within the last 4 weeks.~10. Allergies to mushrooms or other fungi.~11. Significant problems with constipation or diarrhea.~12. Persons exhibiting symptoms of cold\* (\*as defined by TCM) within the past 7 days.~13. A lifestyle or schedule incompatible with the study protocol.~14. Persons who are allergic to yeast products, have autoimmune disease/an immune disorder, or take antidepressants, blood thinners (anticoagulants), or immunosuppressant medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Proglucamune treatment (Type: EXPERIMENTAL): Participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Comparison of Virtual and Real Boxing Training in Hemiparetic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with first time ever stroke~* Patients with hemiparesis~* Patients who are between the ages of 18-70~* Patients who has Mini Mental Test score above 23~* Patients whose functional level is less than 4 according to the Modified Rankin Scale~* Patients who has upper extremity spasticity lower than 3 on Modified Ashworth Scale~Exclusion Criteria:~* Hypertension~* Heart disease~* Subluxation and fracture at the shoulder~* Visual impairment~* Limitation in passive normal joint movement in hemiplegic side~* Botulinum toxin administration or surgical operation in the last 6 months patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- real boxing group (Type: EXPERIMENTAL): In the real boxing (RB) group in addition to the NDT program, real boxing training will be given.
- virtual boxing group (Type: EXPERIMENTAL): In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROSTVAC®-VF/TRICOM™ Vaccine for the Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* Male patients \> 18 years of age who have been vaccinated against smallpox;~* Histological confirmation of adenocarcinoma of the prostate with evidence of metastatic disease including either of the following: Lymph node metastasis measurable by CT and/or Bone metastasis evaluable by bone scan;~* Despite hormone therapy, there is evidence of two consecutive increases in PSA (Prostate Specific Antigen);~* Gleason Score of 7 or lower at initial diagnosis.~Please note that there are additional eligibility criteria that you must meet to qualify.~If you do qualify to participate, study personnel will explain the trial in detail and answer any questions you may have. You can then decide whether or not you wish to participate. If you do not qualify for the trial, study personnel will explain the reasons.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of the rectum~2. Patients who treated with preoperative chemoradiation with fluoropyrimidines followed by curative surgery without microscopic residual tumor.~3. AJCC/UICC pathologic stages of ypT3-4 or ypN+~4. Curative surgery not less than 3 and not more than 8 weeks prior to randomization~5. No prior chemotherapy, radiotherapy and immunotherapy except preoperative chemoradiation for rectal cancer~6. ECOG PS 0-1~7. Adequate organ function~8. Informed Consent~Exclusion Criteria:~1. Macroscopic or microscopic evidence of remaining tumor~2. Any histologic feature other than adenocarcinoma or arisen from chronic inflammatory bowel disease~3. More than 8 weeks after curative surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adjuvant FL (Type: ACTIVE_COMPARATOR): FL (5-FU 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles)
- Adjuvant FOLFOX (Type: EXPERIMENTAL): FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-FU bolus 400 mg/m2 on D1, 5-FU infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject with a Boston Scientific transvenous ICD (de novo implant or upgrade from pacemaker to ICD) implanted because of one of the following:~  * Prior myocardial infarction (MI) and left ventricular ejection fraction (LVEF) ≤ 30% OR~ * Ischemic or non-ischemic cardiomyopathy, and LVEF ≤ 35%, and a New York Heart Association (NYHA) class II or III~* Subject is age 21 or above, or is considered of legal age per given geography~* Subject is willing and capable of providing informed consent~* Subject is willing and capable of complying with follow-up visits as defined by this protocol~Exclusion Criteria:~* History of spontaneous sustained Ventricular Tachycardia (VT) (≥ 160 bpm at ≥ 30 seconds in duration) or Ventricular Fibrillation (VF) not due to a reversible cause~* NYHA Class IV documented in the medical records within 90 calendar days prior to enrollment~* Subject is eligible and scheduled for cardiac resynchronization (CRT) implant~* Subjects with a previous subcutaneous ICD (S-ICD)~* Subject with existing transvenous ICD (TV-ICD) device implanted for greater than 60 days~* Subjects with coronary artery bypass graft surgery or percutaneous coronary intervention within the past 90 calendar days prior to enrollment~* Subjects with documented myocardial infarction within the past 90 calendar days prior to enrollment~* Subjects on the active heart transplant list~* Subject who has a ventricular assist device (VAD) or is to receive a VAD~* Life expectancy shorter than 18 months due to any medical condition (e.g., cancer, uremia, liver failure, etc...)~* Subjects currently requiring hemodialysis~* Subject who is known to pregnant or plans to become pregnant over the course of the trial~* Subject is enrolled in any other concurrent clinical study, with the exception of local mandatory governmental registries and observational studies/registries, without the written approval from Boston Scientific

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATP and Shock (Type: ACTIVE_COMPARATOR): Once tachycardia has been detected and duration met, this group would receive antitachycardia pacing prior to shock therapy.
- Shock only (Type: EXPERIMENTAL): Once tachycardia has been detected and duration met, this group would receive shock therapy only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide informed consent and comply with study assessment for the duration of one year~* Age \>= 25 years~* Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision~* BCVA using ETDRS 20/32 to 20/400~Exclusion Criteria:~* Any history of previous vitrectomy~* Previous cataract or ocular surgery within 2 months of day 0~* Active intraocular inflammation in the study eye~* Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye~* Participation with another investigational drug within the past 30 days~* Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry~* Blood pressure \>180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable)~* Pregnancy

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single Arm study (Type: OTHER): Single arm study:~Drug: ranibizumab intravitreal injection liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cholinergic Augmentation in Frequently Falling Subjects With Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 21~* Diagnosis of Parkinson's disease~* Treated with dopaminergic medication for at least 1 year~Exclusion Criteria:~* Must be ambulatory (can use walker or cane)~* No obvious remediable cause of falls~* Falls are on basis of non-CNS etiologies (cardiogenic, orthopedic, peripheral neuropathy, etc)~* Dementia present (MMSE \< 25)~* Not taking cholinergic or anticholinergic medications 10 days prior to screening visit~* No Warfarin use

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Donepezil (Type: EXPERIMENTAL): None
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bexagliflozin Efficacy and Safety Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of T2DM~* Subjects who have had a stable treatment regimen for T2DM for the past 3 months~* Subjects who present with at least one of the following 3 histories:~Group 1: A history of atherosclerotic vascular disease Group 2: A history of heart failure Group 3: Age ≥ 55 years with diabetes for ≥ 10 years, uncontrolled hypertension, currently smoking, reduced kidney function, or cholesterol problems~Exclusion Criteria:~* Diagnosis of type 1 diabetes mellitus or maturity-onset/diabetes of the young~* History of genitourinary tract infections~* Evidence of abnormal liver function~* History of MI, stroke or hospitalization for heart failure in the past 3 months~* Prior kidney transplant or evidence of kidney problems~* Prior or planned pace maker implantation~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bexagliflozin tablets, 20 mg (Type: ACTIVE_COMPARATOR): Each subject will receive bexagliflozin 20 mg once daily for the duration of the study.
- Placebo tablets (Type: PLACEBO_COMPARATOR): Each subject will receive placebo (inactive tablet) once daily for the duration of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Those who show:~  * Keratoconjunctival disorder confirmed with vital dye staining~ * Abnormal Schirmer score results~Exclusion Criteria:~* Eye disease that needs therapy other than that for dry eye~* Those who need to wear contact lenses during the clinical study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- High concentration (Type: EXPERIMENTAL): None
- Low concentration (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Urinary Track Infection Prevention After Urogynecological Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergo major pelvic organ prolapse surgery that are diagnosed with POUR via failed retrograde void trial and require an indwelling Foley catheter upon hospital discharge.~Exclusion Criteria:~* Unwillingness to participate in the study~* Inability to understand English~* Pregnant women~* Patient personal history of nephrolithiasis, urogenital anomaly, neurogenic bladder, chronic renal insufficiency (GFR \<60 ml/min/1.73 m² or serum creatinine level \>1.03 for \>3months), sarcoidosis, and severe hepatic insufficiency~* Currently (prior 3 months) undergoing medical management for recurrent UTI or interstitial cystitis~* Active urinary tract infection~* Patient history of taking Warfarin (Coumadin)~* Intraoperative bladder injury or cystotomy~* Physical or mental impairment that would affect the subject's ability to take medications daily or fill out questionnaires~* Reported allergy to any of the ingredients in the cranberry, MH, or placebo pill

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Methenamine Hippurate with Cranberry (Type: EXPERIMENTAL): Subjects will be instructed to take Methenamine Hippurate 1 g tablet ( 1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.
- Placebo with Cranberry (Type: PLACEBO_COMPARATOR): Subjects will be instructed to take Placebo tablet (1 tablet twice daily) with Cranberry supplementation (1 tablet twice daily) by mouth starting at time of discharge for 6-8 days.~Cranberry capsules were incorporated into the standard practice of Cincinnati Urogynecology Associates, TriHealth Inc in mid-March 2016.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete